AMICUS THERAPEUTICS, INC. — Director's Dealing 2023

Jul 14, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2023-07-10

Reporting Person: Prout Samantha (Chief Accounting Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	137003	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (right to buy)	$14.88	2028-03-26	Common Stock (2940)		Direct
Stock Options (right to buy)	$10.04	2029-01-02	Common Stock (2376)		Direct
Stock Options (right to buy)	$9.55	2030-01-02	Common Stock (7566)		Direct
Stock Options (right to buy)	$10.03	2030-04-15	Common Stock (13768)		Direct
Stock Options (right to buy)	$21.78	2031-01-04	Common Stock (16963)		Direct
Stock Options (right to buy)	$12.11	2032-01-14	Common Stock (56711)		Direct
Stock Options (right to buy)	$11.93	2033-01-03	Common Stock (55203)		Direct

Footnotes

F1: The amount shown on this line represents Restricted Stock Units which will vest in varying quantities over the next four years, subject in each case to Ms. Prout's continued service with the Company through the applicable vesting dates.

F2: All of the options shown on this line are fully vested and exercisable.

F3: These options were granted on January 2, 2020, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 5,670 options are vested and exercisable and 1,896 remain unvested.

F4: These options were granted on April 15, 2020, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 10,878 options are vested and exercisable and 2,890 remain unvested.

F5: These options were granted on January 4, 2021, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 10,594 options are vested and exercisable and 6,369 remain unvested.

F6: These options were granted on January 14, 2022, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 21,263 options are vested and exercisable and 35,448 remain unvested.

F7: These options were granted on January 3, 2023, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. All of the options shown on this line are unvested.